# Krystal Biotech Krystal Biotech is an Asset Manager based in Pittsburgh, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Pittsburgh, United States - **Region:** North America - **Address:** Pittsburgh, PA, United States - **Founded:** 2015 - **Assets under management:** Undisclosed - **Website:** krystalbio.com ## Regulatory record - **Reports private funds:** No ## About Krish Krishnan, a biochemist with a history of guiding drugs through the FDA at previous ventures, launched Krystal Biotech in Pittsburgh in 2015. The company is built around a herpes-simplex virus type 1 (HSV-1) vector platform. Unlike the adeno-associated viruses (AAVs) most gene therapy companies use — which typically generate neutralizing antibodies after one dose — the HSV-1 backbone is engineered to be re-dosable. That makes the platform a genuine structural outlier in the gene therapy landscape. The wealth origin is institutional venture capital and public-market funding, not a family fortune. The company's strategy is unusual for biotech: it started with a condition too small for most large pharma companies to prioritize. Its lead product, Vyjuvek (beremagene geperpavec), is a topical gel that delivers a functional copy of the COL7A1 gene to skin cells, treating dystrophic epidermolysis bullosa (DEB) — a rare, blistering pediatric disease. The FDA approved Vyjuvek in May 2023. By the end of that year, the company generated roughly $50 million in product revenue, making it one of the few rare-disease launches to achieve meaningful commercial traction in its first two quarters. Beyond DEB, Krystal has expanded its pipeline to aesthetic medicine and larger dermatology indications, filing an IND for a second topical gene therapy targeting aesthetic wrinkles in early 2024. The geographic footprint is heavily US-focused, with all manufacturing in a dedicated Pittsburgh facility and no disclosed clinical operations outside North America. Krystal is listed on Nasdaq and employs approximately 200 people. The company has not disclosed a structured family-office or multi-family-office vehicle, but its commercial revenue and a strong cash position — roughly $700 million in cash and equivalents exiting 2023 — give it a balance sheet that functions like a self-funding investment engine. In June 2024: Filed an Investigational New Drug application for KB301, an aesthetic gene therapy that targets type III collagen to improve skin appearance (per the firm, June 2024). The Pittsburgh headquarters serves as both corporate hub and manufacturing center — an integrated structure that gives Krystal more control over production costs than many biotechs that outsource to CDMOs. The firm's structural differentiator is its balance-sheet independence. Most mid-cap biotechs burn venture capital until a liquidity event or partnership. Krystal turned a rare-disease approval into positive cash flow within months, then fed that capital directly into pipeline expansion and manufacturing scale. That makes its capital-allocation decisions look more like an industrial operator's than a traditional biotech's — a posture reinforced by the husband-and-wife leadership team of Krish and Suma Krishnan, who combine scientific oversight with operational control. ## Sectors - Biotechnology - Gene Therapy ## People - Krish Krishnan — Chairman, CEO & President - Suma Krishnan — Chief Operating Officer ## Questions ### What is Krystal Biotech's core technological platform? Krystal is built on a modified herpes simplex virus type 1 (HSV-1) vector. Unlike the adeno-associated viruses (AAVs) used by most gene therapy companies, HSV-1 vectors do not provoke a strong neutralizing antibody response after a single dose, which makes them re-dosable. The platform is the foundation for the firm's approved topical gel and its pipeline programs in dermatology and aesthetics. ### Who controls day-to-day operations and strategic direction? Krish Krishnan, the founder, serves as Chairman, CEO, and President. Suma Krishnan, a co-founder with a background in drug development, is the Chief Operating Officer. The leadership pair combines scientific oversight — Krish Krishnan holds a biochemistry background and direct FDA-facing experience — with tight operational control of manufacturing and commercialization. ### How does Krystal Biotech fund its operations? Krystal went public on Nasdaq in 2017 and raised capital through equity offerings before the Vyjuvek approval. After the 2023 launch, product revenue began covering a meaningful portion of operating costs. The company held roughly $700 million in cash and equivalents at the end of 2023, allowing it to self-fund pipeline expansion without immediate reliance on dilutive financings or large-scale pharma partnerships (per the firm's financial disclosures, 2023). ### What indications is Krystal targeting beyond rare disease? Krystal is advancing into aesthetics and general dermatology. In June 2024, the company filed an IND for KB301, a topical gene therapy that upregulates type III collagen, targeting aesthetic skin appearance and wrinkles. The firm has also publicly discussed programs in wound healing and broader dermatological conditions, leveraging the same HSV-1 vector platform that delivered Vyjuvek. ### Where does Krystal manufacture its products? All manufacturing takes place at the firm's facility in Pittsburgh, Pennsylvania. Krystal invested early in in-house manufacturing rather than relying on contract development and manufacturing organizations (CDMOs). That vertical integration gives it direct control over the cost, scale, and quality of its gene therapy products. ## Related profiles - [Sirius XM Holdings](https://altss.com/profile/sirius-xm-holdings-inc) - [Full Truck Alliance](https://altss.com/profile/full-truck-alliance-co-ltd) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/krystal-biotech-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology